IDH野生型胶质母细胞瘤与IDH突变型星形细胞瘤长期生存者的神经认知功能:EORTC 1419 ETERNITY报告
ETERNITY研究评估了胶质母细胞瘤长期生存者(≥5年)的神经认知功能纵向变化及其决定因素。在基线(诊断后平均9年),185例患者中145例(78%)至少一项测试受损,总体认知功能随时间基本稳定,肿瘤位置和分子特征与特定认知结局相关。
要点
- 长期生存者中78%存在至少一项神经认知测试受损,受损率从17.4%到58.7%不等。
- 认知功能总体随时间保持稳定,仅延迟记忆出现小幅下降。
- 左侧和颞叶肿瘤位置与较差的神经认知功能相关,额叶位置与更好的精神运动速度和认知灵活性相关。
核心结论
- 多数IDH突变型星形细胞瘤CNS WHO 4级和IDH野生型胶质母细胞瘤长期生存者存在神经认知功能受损,但总体认知功能随时间保持稳定。
研究设计与样本
- ETERNITY为回顾性和前瞻性队列研究,纳入胶质母细胞瘤长期生存(≥5年)患者,本分析 subgroup 为IDH野生型胶质母细胞瘤或IDH突变型星形细胞瘤CNS WHO 4级。
- 神经认知功能在基线和每6个月使用HVLT-R、COWAT和TMT评估,共185例患者纳入分析。
主要发现
- 基线时(诊断后平均9年,范围5-21年),185例中145例(78%)至少一项测试受损。
- 受损率从17.4%(HVLT-R延迟识别)到58.7%(TMT B)不等。
- 神经认知功能随时间基本稳定,HVLT-R延迟记忆有小幅下降。
临床怎么用
- 长期生存者应常规评估神经认知功能,尤其注意左侧和颞叶肿瘤患者。
- 分子特征(IDH突变状态和MGMT启动子甲基化)可辅助预测特定认知领域的变化轨迹。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: ETERNITY was a retrospective and prospective cohort study investigating long-term (≥5 years) survival in patients with glioblastoma. We assessed the longitudinal course of neurocognitive function (NCF) and its determinants in a subgroup of patients with glioblastoma, IDH-wildtype, or astrocytoma, IDH-mutant, CNS WHO grade 4. METHODS: NCF was assessed at baseline and every 6 months using the Hopkins Verbal Learning Test-Revised, Controlled Oral Word Association Test, and Trail Making Test. Scores were converted to age-, sex-, and education-adjusted Z-scores and classified as impaired or unimpaired (Z ≤ -1.5). Linear mixed models were used to analyze NCF trajectories and associations with patient and tumor characteristics. RESULTS: At baseline (mean 9 years post-diagnosis, range 5-21 years), 145 of 185 patients (78%) were impaired on ≥1 test outcome. Impairment rates varied between 17.4% (HVLT-R delayed recognition) and 58.7% (TMT B). NCF remained largely stable over time, with a small decline in HVLT-R delayed memory. Left-sided and temporal tumor location were negatively associated with poorer NCF (p's.01 to.03). Frontal tumor location was associated with higher psychomotor speed and cognitive flexibility (p's <.001). Patients with IDH-mutant tumors performed worse on delayed recognition, whereas IDH mutation and MGMT promoter methylation were linked to improved phonemic fluency over time. CONCLUSIONS: The majority of long-term survivors with astrocytoma, IDH-mutant, CNS WHO grade 4, and glioblastoma IDH-wildtype show neurocognitive impairment. Nonetheless, NCF is generally stable, with tumor location and molecular features associated with specific outcomes. These insights can help guide patient counseling and personalized care.
引用
- Drijver AJ, Butterbrod E, Hertler C, et al. Neurocognitive functioning in long-term survivors of glioblastoma, IDH-wildtype and astrocytoma, IDH-mutant, CNS WHO grade 4: A report from EORTC 1419 (ETERNITY). Eur J Cancer. 2026. PMID: 42607618. doi:10.1016/j.ejca.2026.116985
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。